Bio Path Other Stockholder Equity Over Time
| BPTH Stock | USD 0.82 0.02 2.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bio Path Performance and Bio Path Correlation. Bio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Bio Path Holdings and related stocks such as Catalyst Biosciences, Diffusion Pharmaceuticals, and Capricor Therapeutics Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | 99.0 | 45.6 M | 46.5 M | 15.6 M | 16.1 M | 34.1 M | 50 M | 62.7 M | 71.3 M | 81.2 M | 116.2 M | 139.4 M | 148.7 M | 181.7 M | 190.8 M |
| NXTC | 867 K | 867 K | 867 K | 867 K | 867 K | 867 K | 867 K | 867 K | 2.8 M | 46.4 M | 410.6 M | 421 M | 430.8 M | 439.1 M | 275.2 M |
| PULM | 28 K | 28 K | (45.9 M) | 18.3 M | (18.6 M) | 160.7 M | 167.4 M | 187 M | 208.5 M | 226.2 M | 257.6 M | 301 M | 304.6 M | 305.6 M | 175.4 M |
| CRNX | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (28.2 M) | (171.5 M) | (210.9 M) | (336.5 M) | (607.2 M) | (755.5 M) | (680 M) | (646 M) |
| ALRN | 4 K | 4 K | 4 K | 4 K | 4 K | 3.8 M | 4.6 M | 132.1 M | 188.1 M | 214.1 M | 231.4 M | 289.3 M | 291.4 M | 204 M | 171.5 M |
| BNTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.66 | 0.0 | 128.8 M | 151.6 M | 152.5 M | 168.9 M | 238.4 M | 250.3 M |
| MBRX | (3 K) | (3 K) | (3 K) | (3 K) | (3 K) | (3 K) | 19.6 M | 31.6 M | 40.6 M | 55.1 M | 74.5 M | 151.7 M | 154 M | 157.7 M | 83.7 M |
| ACHV | 500 K | 109 M | 165.4 M | 168.2 M | 191.4 M | 211.6 M | 213.2 M | 20.6 M | 41.2 M | 63.7 M | 97.6 M | 121.5 M | 144.1 M | 164.2 M | 156 M |
| AKTX | 9.9 M | 9.9 M | 13.3 M | 25.7 M | 34.1 M | 87 M | 91 M | 104.8 M | 104.8 M | 122.3 M | 191.9 M | 205.3 M | 219.3 M | 174.8 M | 117.1 M |
Bio Path Holdings and related stocks such as Catalyst Biosciences, Diffusion Pharmaceuticals, and Capricor Therapeutics Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Bio Path Holdings | BPTH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.82
Check out Bio Path Performance and Bio Path Correlation. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Bio Path technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.